The only anti-IgE antibody medication currently on the market in the United States is omalizumab. This medication has been classified by the U.S. Food and Drug Administration (FDA) in pregnancy risk category B. This means clinical testing in animals did not demonstrate any toxic effects on the animal fetuses. Though there has not yet been testing in humans, the FDA believes this medication should not interfere with human pregnancy. Pregnant women should always discuss their condition with their physicians before taking any medication.

It is still unclear whether omalizumab can be passed on to nursing children during breastfeeding. Natural occurring IgE is secreted in human milk, and many physicians believe this means it is likely that omalizumab can also be present – though probably in a highly diluted state. Though there is no evidence that omalizumab is capable of harming a nursing child, breastfeeding mothers should use caution and speak with their physicians before taking this medication.